Cytogenetic Effects Of Fumagillin On Male Mice (Mus musculus)
Article Sidebar
Main Article Content
Abstract
The cytogenetic effects of Fumagillin were evaluated according to Mitotic Index (M.I) and aberration of metaphase chromosomes in bone marrow cells(CA) of white mice. The fumagillin was given as repeated oral gavages for 7 successive days after preparing the doses 10,15 at concentrations 20 mg/kg.b.wt. in 50% of sugar syrup . The positive control was given single I.p. dose of 20 mg/kg.b.wt. of methotrexate. The three dosages 10, 15, and 20 mg/kg.b.wt of Fumagillin induced significant decrease in mitotic index (3.90 ± 0.29, 3.60 ± 1.80, and 2.90 ±0.18) respectively compared with (7.10 ±0.29) for negative control. The results showed that the two dosages 15 and 20 mg/kg.b.wt of Fumagillin induced significant increase in the frequency of the chromosome aberration in bone marrow cells of the mice in the these groups (9.00± 0.92, 17.20 ± 1.42) respectively compared with (6.00 ±0.83) for negative control. The obtained result revealed the genetic and cellular toxic reaction of Fumagillin within the high and medium limits studied doses.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1. Molina, J.M., Goguel, J., Sarfati, C., Michiels,
J.F., Desportes Livagel, I. and S. Balkan (2000). Trial
of oral fumagillin for the treatment of intestinal
microsporidiosis in patients with HIV infection.
AIDS, 14, 1341-1348.
2. Conteas, C.N., Berlin O.G., Ash, L.R., and Pruthi,
J.S. (2000). Therapy for human gastrointestinal
microsporidiosis. Am. J. Trip. Med. Hyg. 63, 121-
127.
3. Morris, D.J., Adams, A., Smith, P. and R.H.
Richards (2003). Effects of oral treatment with TNP-
470 on rainbow trout (Oncorhynchus myksis)
infected with Tetracapsuloides bryosalmonae
(Malacosporea), the causative agent of proliferative
kidney disease. Aquaculture, 221, 51-64.
4. El-Matbouli, M., and Hoffmann R.W. (1991).
Prevention of experimentally induced whirling
disease in rainbow trout Oncorhynchus mykss by
Fumagillin. Dis. Aquat. Oragn. 10, 109-113.
5. Bailey, L. (1953). Effect of fumagillin upon
Nosema apis (Zander).Nature 171, 112-213.
6. Katznelson, H. and C.A. Jamieson (1952). Control
of Nosema disease of honey-bees with fumagillin.
Science 115, 70-71.
8. Furgala, B., (1962). Residual fumagillin activity
in sugar syrup stored by wintering honey bee
colonies. J. Apic. Res. 1, 35-37.
9. Assil, H.I. and P. Sporns, (1991). ELISA and
HPLC methods for analysis of fumagillin and its
decomposition products in honey. J. Agric. Food
Chem., 39, 2206-2213.
10. Liu, T.P., (1990a). Ultrastructure of mitochondria
in the corpora allata of honeybees infected by
Nosema apis before and after treatment with anti-
Nosema drugs. Tissue Cell, 22, 511-515.
11. Rada, V., Machova, M., Huk, J., Marounek, M. and
D. Duskova(1997). Microflora in the honeybee digestive
tract -counts, characteristics and sensitivity to veterinary
drugs. Apidologie, 28, 357-365.
12. Stanimirović, Z., Stevanović, J., Bajić, V. and I.
Radović(2007).Evaluation of genotoxic effects of
fumagillin bycytogenetic tests in vivo. Mutat. Res.
628, 1–10.
13. Stevanović, J., Stanimirović, Z., Radaković, M.,
and V. Stojić(2008). In vitro evaluation of the
clastogenicity of fumagillin. Environ. Mol. Mutagen.
49, 594-60.
14. Ames, B.N., (1989). Mutagenesis and
carcinogenesis: Endogenous and exogenous factors.
Environ. Molec. Mutl. 14, Suppl. 16, 66-77.
15. Hsu, T.C. and G.L., Patton (1969). Bone marrow
preparations for chromosome studies. In :
Comparative mammalian cytogenetics. (Ed.
Benirschke), 1-395. Springer-Verlag, Berlin.
16. Zimonjić, D.B., Savković, N. and M. Andjelković
(1990). Genotoksičniagensi: efekti, principi i
metodidetekcije, 1-395, Naučnaknjiga, Beograd.
17. Mazzanti C.M., Tandle, A., Lorang, D., Costouros,
N., Roberts, D., Bevilacaqua, G., and S.K. Libutti
(2004). Early genetic mechanisms underlying the
inhibitory effects of endostatin and fumagillin on
human endothelial cells. Genome Res. 14, 1585-1593.
18. Wang J., Lou, P. and J. Henkin(2000). Selective
inhibition of endothelial cell proliferation by
fumagillin is not due to differential expression of
methionine aminopeptidases. J. Cell. Biochem. 77,
465–473.
19. Ingber D., Fujita, T., Kishimoto, S., Sudo, K.,
Kanamaru, T., Brem, H. and J. Folkman (1990).
Synthetic analogues of fumagillin that inhibit
angiogenesis and suppress tumour growth. Nature,
348, 555-557.
20. Fardis M., Pyun, H.J., Tario, J., Jin, H., Kim,
C.U., Ruckman, J., Lin, Y., Green L. and B. Hicke
(2003). Design, synthesis and evaluation of a series of
novel fumagillin analogues. Bioorg. Med. Chem. 11,
5051-5058.
21. Stanimirović, Z., Stevanović, J. and D.
Pejović(1999). Analysis of genotoxic effects
Fumagilin R-ET. In: Proceedings of 29thAnnual
Meeting of the European Environmental Mutagen
Society EEMS-99 (85), Copenhagen, 44-45.
22. Stevanović, J., Stanimirović Z., Djelić, N. and S.
Djurković(2000). Is the application of fumagillin in
nosemosis treatment acceptable from a
genotoxicological point ofview. Proceedings of the
2nd Symposium in Animal Clinical Pathology and
Therapy Clinical Veterinaria2000, Budva, 227-230.
23. Kulic, M., (2006). Research on genotoxic
potential of dicyclohexylamine in vivo and in vitro.
Ph.D. Thesis, Faculty of Biology, University of
Banjaluka.
24. Purchase, I.F.H., Longstaff, E., Ashby, J., Styles,
J.A. and D. Anderson (1978). An evaluation of six
short-term tests for detectingorganic chemical
carcinogens. Br. J. Cancer, 37,873-959
25. Mortelmans, K., Haworth, S. Lawlor, T., Speck,
W., Tainer, B. and E. Zeiger (1986). Salmonella
mutagenicity test: II. Results from testing of 270
chemicals. Environ. Mutagen. 8 (Supl. 7), 1-119.
26. Stoltz, D.R., Khera, K.S., Bendall, R. and S.W.
Gunner (1970).Cytogenetic studies with cyclamat and
related compounds. Science 167, 1501-1502.
27. National Toxicology Program (2006a)
http:/ntp.niehs.nih.gov/index.cfm?objectid=6DEOB8
8C-FIF6-975E-7A19428A3AD94D8s.
28. National Toxicology Program (2006b).
htpp://ntp.niehs.nih.gov/index.cfm?objectd=6DEOE4
3F 1F6-975E-7BOFA8000DO56A43.
29. Mladjan, V., and Jovic ,M. (2000). Antibiotics in
beekeeping. Proceedings of the 2nd Symposium in
Animal Clinical Pathology and Therapy, Clinica
Veterinaria, Budva, 211-212.
30. Stanimirović Z, Stevanović, J., Kulić, M. and V.
Stojić (2006). Frequency of chromosomal aberrations
in evaluation of genotoxic potential of
dicyclohexylamine (fumagilline) in vivo. Acta Vet. 4,
353-366
31. Stevanović, J., Stanimirović, Z., Pejin, I. and M.
Lazarević (2006). Monitoring of mitotic index and
frequency of micronuclei in evaluation of genotoxic
potential of fumagillin (dicyclohexylamine) in vivo.
Acta Vet. 56,437-448.